

# Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 9:30 a.m. ET in New York, NY.

A live webcast of the presentation will be available on the News and Events section of the Company's website at [www.cabalettabio.com](http://www.cabalettabio.com). Replays will be available on the website for 30 days.

## About Cabaletta Bio

Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio's headquarters and labs are located in Philadelphia, PA. For more information, please visit [www.cabalettabio.com](http://www.cabalettabio.com) and connect with us on LinkedIn.

## Contacts:

Anup Marda  
Chief Financial Officer  
[investors@cababio.com](mailto:investors@cababio.com)

Cabaletta Bio®

Source: Cabaletta Bio